Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow aTYR PHARMA INC

Get SEC filing alerts via email and in your feed for aTYR PHARMA INC

LIFE ATYR

aTYR PHARMA INC

About aTYR PHARMA INC

aTyr Pharma, Inc. is a biotechnology company focused on developing therapies for fibrosis and inflammation using its proprietary platform based on extracellular tRNA synthetase biology. Its lead candidate, efzofitimod, is a biologic immunomodulator targeting immune-mediated lung diseases like sarcoidosis and ILD. The company advances novel biologics, collaborates globally, and relies on third-party manufacturing, aiming to address unmet medical needs with innovative, mechanism-based treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from aTYR PHARMA INC

1
1
aTYR PHARMA INC aTyr Pharma Reports $10.8 Million Net Loss in Q1 2026, Terminates Collaboration with Kyorin

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
aTYR PHARMA INC aTyr Pharma Reports $74.1 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
aTYR PHARMA INC aTyr Pharma Reports $190,000 Revenue in Q3 2025, Faces $25.7 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
aTYR PHARMA INC aTyr Pharma Reports $19.5 Million Net Loss in Q2 2025, No Revenue Generated

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
aTYR PHARMA INC aTyr Pharma Reports Q1 2025 Financial Results with $14.9 Million Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
aTYR PHARMA INC aTyr Pharma Reports $64M Net Loss for Fiscal Year 2024, Decreased Revenues and Increased R&D Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
aTYR PHARMA INC aTyr Pharma Reports Significant Financial Challenges, No Revenue in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments